ERBB2 Gene Amplification clinical trials at UC Health
1 research study open to eligible people
Experimental Medicine (Transuzumab and Pertuzunab) in Advanced Colorectal Cancer with Genetic Component
“Help us examine how well experimental drugs work compared to standard-use drugs in treating colorectal cancer.”
open to eligible people ages 18 years and up
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and irinotecan hydrochloride in treating patients with colorectal cancer.
at UC Irvine UC Davis